Compare MCB & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | DRTS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2021 |
| Metric | MCB | DRTS |
|---|---|---|
| Price | $94.04 | $14.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $98.67 | $8.67 |
| AVG Volume (30 Days) | 134.4K | ★ 569.0K |
| Earning Date | 04-21-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | ★ $11,053,000.00 | N/A |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | $699.98 |
| P/E Ratio | $21.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $64.66 | $3.01 |
| 52 Week High | $102.04 | $14.75 |
| Indicator | MCB | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 61.69 |
| Support Level | $86.40 | $6.59 |
| Resistance Level | $94.08 | N/A |
| Average True Range (ATR) | 2.12 | 0.72 |
| MACD | 0.18 | 0.14 |
| Stochastic Oscillator | 70.98 | 84.43 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.